Scientific Program



Breast Cancer



Ovarian Cancer



Endometrial Cancer



Cervical Cancer

Live Stream from Berlin – in Tv Quality

Chat Window: Discuss with us! Send us your questions and comments!

Presidential Lectures
Scientific Lectures
Pro/Con Debates
State of the Art Sessions
Educational Sessions
CMC Panel Discussions
Symposia

Download Program PDF

Part I: Breast Cancer

Immunotherapy
ADCs and Combinations
Endocrine Therapies for Early Breast Cancer High-risk Patients
Overcoming Endocrine Resistance for Advanced Breast Cancer Patients
Role of HER2
Local Therapies and Breast Reconstruction

Part II: Ovarian Cancer

What is the Best Therapy for Platinum-resistant Ovarian Cancer?
Let Us Find Better Definitions for Platinum Resistance
Prehabilitation for Sugery
HRD Negative / Platinum Resistance
Neoadjuvant vs. Interval vs. Delayed vs. No Surgery
ADCs

Part III: Endometrial Cancer

Checkpoint Inhibition
Sentinel Node
Prehabilitation for Medical Therapies
Molecular Classification – What are the Limits, What are the Clinical and Scientific Sequelae?
ADCs

Part IV: Cervical Cancer

Prevention
Checkpoint Inhibition
ADCs

Part V: Miscellaneous

Best Immunotherapy in Gynecological Cancer
What are the Most Promising Agents in the Current Phase I and II Landscape?
Endometriosis-induced Cancer – Are they Really Different?
How can We Translate our Phase III Trials into Clinical Practice?
How can We Better Manage Women’s Cancer in Regions with Limited Resources?
How do We Define and Address Time Toxicity in Our Clinical Practice?

Status: November 2025; may be subject to change.